---
schema_version: "secwatch.filing_event.v1"
accession: "0001641172-25-002774"
form_type: "8-K"
ticker: "CDT"
cik: "0001896212"
company_name: "CDT Equity Inc."
filed_at: "2025-04-04T23:59:59+00:00"
generated_at: "2026-05-23T21:23:18.855672+00:00"
event_type: "other_material"
sentiment: "neutral"
materiality_score: 0.6
calibrated_materiality_score: 0.6
confidence: "high"
source: SEC EDGAR
---

# Conduit Pharmaceuticals enters AI analytics deal for AstraZeneca assets; issues 2.26M shares

## Summary
- Entered additional agreement with Sarborg for AI analysis of AZD1656, AZD5658, AZD5904 clinical data to identify repurposing opportunities.
- Agreement term six months, total consideration $2.0M (cash or stock at company's election).
- Issued 1,853,933 shares to satisfy ~$1.65M of fees; also issued 410,113 shares for consulting services.
- Company had 9,549,800 shares outstanding as of March 31, 2025.
- Aim is to re-evaluate failed endpoints from AstraZeneca trials to identify benefited patient subgroups.

## SEC filing metadata
- accession: 0001641172-25-002774
- form_type: 8-K
- ticker: CDT
- cik: 0001896212
- company_name: CDT Equity Inc.
- filed_at: 2025-04-04T23:59:59+00:00
- event_type: other_material
- sentiment: neutral
- materiality_score: 0.6
- calibrated_materiality_score: 0.6
- confidence: high
- sec_items: 1.01, 3.02
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1896212/000164117225002774/0001641172-25-002774-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1896212/000164117225002774/form8-k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001641172-25-002774
- JSON: https://secwatch.observer/filing/0001641172-25-002774.json
- Plain text: https://secwatch.observer/filing/0001641172-25-002774.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.